Document is current
Any future updates will be listed below
-
Authors
Pacilli, Annalisa
Rotunno, Giada
Mannarelli, Carmela
Fanelli, Tiziana
Pancrazzi, Alessandro
Contini, Elisa
Mannelli, Francesco https://orcid.org/0000-0003-4810-6501
Gesullo, Francesca
Bartalucci, Niccolò https://orcid.org/0000-0002-9328-3948
Fattori, Giuditta Corbizi
Paoli, Chiara
Vannucchi, Alessandro M. https://orcid.org/0000-0001-5755-0730
Guglielmelli, Paola https://orcid.org/0000-0003-1809-284X
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (21267, 21267, 21267, 21267, 21267, 21267, 21267, 21267, 21267, 21267, 15967, 21267)
Istituto Toscano Tumori (B16D14001130002, B16d14001130002)
Ministero della Salute (GR-2011-02352109)
- License Information
-
More Information
Article History
Received: 11 September 2018
Revised: 27 September 2018
Accepted: 15 October 2018
First Online: 22 November 2018
Conflict of interest
: A.M.V. was involved in clinical trials with ruxolitinib, participated to advisory boards and speaker bureau for Novartis, and received institutional research grants from Novartis. All remaining authors declare no conflict of interest.
